Tevogen Bio (NASDAQ:TVGN) Given Buy Rating at D. Boral Capital

Tevogen Bio (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating restated by equities researchers at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock.

Tevogen Bio Price Performance

Shares of TVGN traded up $0.03 during trading hours on Tuesday, reaching $1.01. 767,410 shares of the company traded hands, compared to its average volume of 5,099,761. The business has a fifty day moving average price of $1.09 and a 200-day moving average price of $1.32. Tevogen Bio has a 12-month low of $0.26 and a 12-month high of $3.09.

Insider Activity

In related news, insider Neal Flomenberg sold 70,384 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $1.09, for a total value of $76,718.56. Following the sale, the insider now owns 3,898,828 shares in the company, valued at $4,249,722.52. This represents a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 406,510 shares of company stock valued at $446,763. Company insiders own 56.60% of the company's stock.

Institutional Trading of Tevogen Bio

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in shares of Tevogen Bio by 31.2% during the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock worth $465,000 after purchasing an additional 107,566 shares during the last quarter. XTX Topco Ltd acquired a new stake in Tevogen Bio during the 4th quarter worth about $55,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Tevogen Bio during the 4th quarter valued at about $38,000. JPMorgan Chase & Co. lifted its holdings in shares of Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after buying an additional 16,695 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Tevogen Bio by 13.0% in the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after buying an additional 13,595 shares during the last quarter.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.